Attention-Deficit / Hyperactivity Disorder (ADHD)

What ADHD is

ADHD is a neurodevelopmental condition: it starts in childhood, runs in families, and reflects differences in how networks in the frontal cortex, striatum and cerebellum mature and work together. The core difficulties — sustaining attention, controlling impulses, regulating activity, and managing effort across time — produce predictable problems in school, relationships and daily life when no support is in place. Importantly, ADHD is not a problem of intelligence, motivation or upbringing.

Three presentation types are recognised in DSM-5: predominantly inattentive (often missed in girls), predominantly hyperactive-impulsive (more obvious in younger boys), and combined. Presentations can change with age and context.

How it presents

• Inattention: trouble sustaining focus on schoolwork, careless mistakes, losing things, distractibility, forgetfulness, difficulty starting and finishing tasks
• Hyperactivity-impulsivity: restlessness, fidgeting, talking excessively, interrupting, struggling to wait, acting before thinking
• Symptoms must be present in more than one setting (home and school), have begun before age 12, and cause clear impairment to qualify for the diagnosis
• Executive-function difficulties (organising, planning, switching, working memory) are common and often more disabling than the textbook symptoms
• Co-occurring problems are the rule rather than the exception — anxiety, learning differences, autism spectrum features, motor coordination problems, sleep difficulties and emotional dysregulation

How it is diagnosed

Diagnosis is clinical — there is no blood test, scan or computerised attention task that establishes or rules out ADHD. A good assessment combines structured information from parents and teachers (using validated questionnaires such as Vanderbilt, Conners, SDQ or SNAP), direct observation of the child, a developmental and family history, and a careful look for co-occurring or alternative explanations (sleep apnoea, thyroid disease, learning disability, anxiety, post-traumatic features, hearing or vision problems, substance use in adolescents).

Computerised tests (continuous performance tests, e.g. QbTest, IVA) and EEG-based markers add information in selected cases but cannot replace clinical assessment. Genetic testing is not currently routine in ADHD.

Standard pharmacological treatment

Medication is one of the most effective treatments in all of paediatric psychiatry, with effect sizes around 0.7–1.0 for core symptoms — larger than for most behavioural interventions. Around 70–80% of children respond well to a first or second stimulant trial when titration is done carefully.

• Stimulants are first-line: methylphenidate-based (immediate-release, extended-release such as Concerta, Equasym XL, Medikinet XL, lisdexamfetamine prodrug Elvanse) and amphetamine-based formulations. Response and side-effect profiles differ between the two stimulant families — if one is not tolerated or doesn't work, the other should be tried before moving on
• Non-stimulants are used when stimulants are not tolerated, are contraindicated, or in children with prominent tic disorders, anxiety, sleep difficulties or substance-misuse risk: atomoxetine (selective NRI), guanfacine ER (alpha-2A agonist), clonidine ER (alpha-2 agonist), and viloxazine ER (Qelbree, approved 2021)
• Selection considers age, comorbidities, sleep, appetite, cardiovascular history, ability to swallow tablets, and family preference
• Common manageable side effects: appetite suppression, sleep onset delay, headaches, mood changes, mild blood-pressure or heart-rate effects
• Routine monitoring of growth, blood pressure and heart rate is standard; a baseline cardiac history is taken but routine ECG is not required in low-risk children

The new and upcoming drug pipeline

ADHD pharmacology is moving for the first time in years. The most significant 2025–2026 development is centanafadine.

• Centanafadine (Otsuka) — a first-in-class triple reuptake inhibitor (serotonin + norepinephrine + dopamine, in roughly that order of potency). A Phase 3 study in 327 children aged 6–12 reported significantly greater symptom reduction than placebo (34% achieved a clinically meaningful response in the high-dose group vs 23% on placebo), with a tolerability profile favourable compared with stimulants. The FDA accepted Otsuka's NDA in late 2025 with Priority Review; the PDUFA target action date is 24 July 2026 for children, adolescents and adults. If approved, it would be the first new oral ADHD medication for children in years
• Solriamfetol (Sunosi, a dopamine/norepinephrine reuptake inhibitor used for narcolepsy) is in Phase 3 trials for adult ADHD; paediatric data are not yet available
• Several earlier-stage candidates remain in development; some (dasotraline, mazindol ER) have been discontinued

Behaviour, education and parenting support

Medication treats the underlying neurobiology, but it does not by itself teach skills, change school environments, or repair strained family dynamics. The combined-treatment arm of the MTA study, the largest paediatric ADHD trial, found the best long-term outcomes in children who received both medication and structured behaviour therapy — not medication alone.

• Parent training programmes (e.g. Triple P, Incredible Years, NICE-recommended group parent training) — strong evidence in younger children, often first-line before 6 years
• Behavioural classroom interventions, daily report cards, structured break systems, fidget tools used purposefully
• School accommodations (extra time, frequent breaks, preferential seating, chunked instructions, visual supports) — these belong in a formal SEND/IEP plan in the UK and a 504 Plan/IEP in the US
• Cognitive-behavioural therapy (CBT) for older children and adolescents to target executive function, organisation and self-esteem, and to manage co-occurring anxiety/depression
• Social-skills training where peer difficulties are prominent

Digital therapeutics and neuromodulation

A new category of non-drug, non-talking treatments has emerged in the last few years, all FDA-cleared:

• EndeavorRx (Akili Interactive) — a prescription video-game treatment for children aged 8–12 with primarily inattentive or combined ADHD. FDA-cleared in 2020 on the basis of the STARS-ADHD trial, where 8 weeks of gameplay produced a modest improvement on a computerised attention measure compared with a control video game. Real-world effect on classroom function is more modest than for stimulants, but it is a useful adjunct, particularly when families are wary of medication or while titration is in progress
• Monarch external trigeminal nerve stimulation (eTNS) — a non-invasive device worn at night that delivers low-level stimulation to the trigeminal nerve via a forehead patch. FDA-cleared in 2019 for children aged 7–12 with ADHD as monotherapy. Evidence base is small but consistent for modest reductions in ADHD-RS scores after 4–8 weeks; mild skin irritation is the commonest side effect
• Repetitive transcranial magnetic stimulation (rTMS) targeting the dorsolateral prefrontal cortex — 2025 systematic reviews and meta-analyses suggest meaningful effects on attention and processing speed in children and adolescents, but the evidence base is still smaller and less standardised than in adult depression; rTMS for paediatric ADHD remains investigational outside clinical trials
• Transcranial direct-current stimulation (tDCS) — small paediatric studies report short-term improvements; technique, dose and sham control still vary widely

Neurofeedback, cognitive training and other complementary approaches

Several non-drug interventions are heavily marketed to families. The evidence varies, and an honest review should distinguish what works well, what works modestly, and what mostly reflects non-specific support.

• Neurofeedback (EEG biofeedback) — children learn to modulate their own EEG patterns (typically reducing theta and increasing beta or training SCP) over 30–40 sessions. Meta-analyses show small to moderate benefit on parent-rated symptoms, but blinded teacher ratings and active-control studies suggest much of the effect is non-specific; some children clearly do benefit, particularly when combined with behavioural therapy
• Cognitive training (e.g. Cogmed working-memory training) — improves performance on the trained tasks but transfer to real-world attention or schoolwork has been modest and inconsistent in trials
• Physical exercise — the most under-appreciated intervention; regular moderate-to-vigorous activity has small-to-moderate effects on attention and executive function, and large effects on sleep and mood, with no downside
• Mindfulness-based interventions — modest effects in adolescents, useful particularly where anxiety or emotional dysregulation are prominent
• Sleep optimisation — undiagnosed obstructive sleep apnoea, restless legs syndrome or delayed sleep phase can mimic or worsen ADHD; investigating and treating these is high-yield
• Diet: omega-3 supplementation has a small but real effect on symptoms (effect size ~0.2); few-foods (oligoantigenic) diets help a subset of children with definite food triggers but require dietetic supervision; iron and zinc supplementation only help when deficient; 'sugar' has not been shown to cause ADHD symptoms in blinded trials
• Yoga and martial arts — small studies suggest benefit on attention and self-regulation; reasonable as adjuncts

Across the lifespan

About half of children with ADHD continue to meet diagnostic criteria as adults, and many more retain residual difficulties even when they fall below the formal threshold. Untreated ADHD is associated with poorer educational and occupational outcomes, higher rates of accidents and traffic offences, earlier substance use, and higher rates of anxiety and depression. Well-managed, the gap closes substantially.

Transition from paediatric to adult ADHD services is one of the weakest links in many health systems and is a frequent reason families seek a second opinion — both to confirm the diagnosis and to plan medication, study and work support into adulthood.

How an educational review can help

If you are wondering whether your child's difficulties might be ADHD, or you want a second look at an existing diagnosis or treatment plan, an educational review can pull together the reports, rating scales, school information and any previous trials of medication or therapy, and explain the options in plain language — including how to weigh medication, behaviour therapy, school accommodations, digital and neuromodulation tools, and lifestyle factors against each other. It is educational and supports your treating clinicians.